Morningstar

Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma ...

Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee ...
MedPage Today

Gabriel Hortobagyi on a New Postneoadjuvant Prognostic Staging System for Breast Cancer

A novel prognostic staging system predicted survival for patients with breast cancer after neoadjuvant chemotherapy (NACT), addressing an unmet need, researchers reported. One of the benefits of ...
Morningstar

Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage ...

Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk ...
ascopubs.org

Combining machine learning with the immunohistochemical expression of AMBRA1 and loricrin to identify non-ulcerated AJCC stage I/II melanomas at high-risk of metastasis.

Rational use of adjuvant anti-PD-1: Multi-omics model of recurrence in stage III melanoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full ...
Midland Daily News on MSN

Mayo Clinic Q&A: Advances in staging and surgical treatment of melanoma

Mayo Clinic Q&A: A look at the advances in staging and surgical treatment of melanoma.